Objective: APOE status has been associated to affective symptoms in cognitively impaired subjects, with conflicting results. Methods: Databases CINAHL, Embase, PsychINFO and PubMed were searched for studies evaluating APOE genotype with affective symptoms in MCI and AD dementia. Symptoms were meta-analyzed separately and possible sources of heterogeneity were examined. Results: Fifty-three abstracts fulfilled the eligibility criteria. No association was found between the individual symptoms and APOE ε4 carriership or zygosity. For depression and anxiety, only pooled unadjusted estimates showed positive associations with between-study heterogeneity, which could be explained by variation in study design, setting and way of symptom assessment. Conclusions: There is no evidence that APOE ε4 carriership or zygosity is associated with the presence of depression, anxiety, apathy, agitation, irritability or sleep disturbances in cognitively impaired subjects. Future research should shift its focus from this single polymorphism to a more integrated view of other biological factors.
Introduction
Affective symptoms are considered a core feature of Alzheimer's disease (AD) dementia as they are highly prevalent and occur in nearly all patients over the disease course, including in its prodromal phase (i.e. mild cognitive impairment, MCI) (Aalten et al., 2007; Steinberg et al., 2008; Zhao et al., 2016; Apostolova and Cummings, 2008; Monastero et al., 2009) . Heterogeneity in the expression of affective symptoms in cognitively impaired subjects is thought to be associated with genetic variability. Apolipoprotein E (APOE) is the most important and well-documented genetic risk factor for late onset AD (Hollingworth et al., 2011) and additionally, might impact disease phenotypes, such as manifestations of affective symptomatology.
The APOE gene is polymorphic, having three common alleles (ε2, ε3 and ε4) that alter APOE structure and function, which has implications for all AD related biochemical disturbances . Whereas the prevalence of ε4-carriers in the general population is estimated around 14%, among amyloid-beta positive subjects with MCI and AD dementia it is as high as 65% (Bertram et al., 2018; Mattsson et al., 2018) . Carrying the ε4-allele increases the risk to develop AD dementia, with ε4-heterozygotes having a two-to-four fold high risk and ε4-homozygotes having a 12-fould higher risk compared to non-carriers (Bertram et al., 2007) .
The most common symptoms in subjects with MCI and AD dementia are, albeit in a different order per disease stage, depression, anxiety, agitation, apathy, irritability and sleep disturbances (Zhao et al., 2016; Apostolova and Cummings, 2008; Monastero et al., 2009; Geda et al., 2008; Lyketsos et al., 2002) . These affective symptoms accelerate disease progression (Donovan et al., 2014) , are considered to be risk factors for neurocognitive disorders (Geda et al., 2014; Cherbuin et al., 2015; Cooper et al., 2015; Gulpers et al., 2016) , and some have been associated with AD biomarkers (Ramakers et al., 2013) . Their presence has a huge impact on both patients' and caregivers' quality of life (Black et al., 2012) , results in higher institutionalization rates (Afram et al., 2014) and increased health care costs (Herrmann et al., 2006) . This underlines the importance of determining mechanisms implicated in affective symptomatology, thereby possibly opening a way for earlier and more personalized treatment options. APOE genotype has been related to affective symptoms in subjects with MCI and AD dementia, however, results are equivocal. Two previous reviews attributed this to differences in study design, study setting, subject characteristics, the use of different instruments to assess https://doi.org/10.1016/j.neubiorev.2018.11.020 Received 17 July 2018; Received in revised form 24 October 2018; Accepted 30 November 2018 affect or different definitions (symptom vs. disorder) (Flirski et al., 2011; Panza et al., 2012) . Additionally, whereas some studies evaluated associations dichotomously (i.e. non-carrier vs. carrier of at least one APOE ε4 allele), others have examined dose effect of APOE ε4 alleles (i.e. hetero-and homozygosity). However, these reviews did not perform a systematic search of the literature and did not address the suggested methodological differences in a quantitative manner (Flirski et al., 2011; Panza et al., 2012) . Therefore, this systematic review and meta-analysis aims to provide a comprehensive summary of the evidence on the association between APOE status and affective symptomatology in cognitively impaired subjects.
Methods
This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Liberati et al., 2009 ). The literature search was conducted in databases CINAHL, Embase, PsychINFO and PubMed that were searched to October 2017. The search string consisted of population related terms (e.g. cognitive impaired, dementia, AD), predictor related terms (APOE ε4 genotype), of outcome-related terms (affective symptoms) and of specific limitations (e.g. humans, language restrictions). A full description of the search strategy is provided in Appendix 1, in Supplementary material.
The symptoms depression, anxiety, apathy, agitation, irritability, sleep disturbances were chosen as these are the most common symptoms in MCI and AD dementia (Zhao et al., 2016; Apostolova and Cummings, 2008; Monastero et al., 2009; Geda et al., 2008; Lyketsos et al., 2002) . Further, these symptoms have most often been grouped together in factor analyses, e.g. "agitation, depression, anxiety and irritability", or "depression, anxiety, apathy and irritability" (Canevelli et al., 2013) .
To be eligible for inclusion, publications fulfilled the following criteria: a) is population or clinically based and explicitly defines a cognitive impairment; b) assesses the current presence and/or severity, by self-or proxy-report, of the following symptoms: depression, anxiety, apathy, agitation, irritability, sleep disturbances and/or subsyndromes; c) examines the association between affective symptoms and APOE genotype. Studies were excluded if the study sample included a) non-AD dementia types (e.g. vascular dementia (VaD), Lewy body disease (LBD), frontotemporal dementia (FTD), Parkinson's disease (PD)) or, in case this was defined, vascular cognitive impairment (VCI); b) primary somatic or psychiatric patients in whom cognition is studied (e.g. patients with major depression).
Two reviewers (L.B. and I.R.) independently screened titles and abstracts for potential eligibility. Doubtful records were discussed until consensus was reached. Records of research protocols, and abstracts/ posters from scientific meetings were excluded. Reference lists of retrieved publications and secondary literature (review articles, editorials, etc.) were screened to identity possible additional studies. Eligibility for inclusion was assessed based on full-text screening.
Data collection and extraction
According to a predefined data extraction form, data on the design, sample size and demographics of the included studies, as well as characteristics of the biomarkers and affective symptoms (assessment and diagnostic definition (symptom vs. disorder)) were extracted. Quantifiable data on the relation between biomarker and affective symptoms were extracted. In case studies provided demographic information per group, weighted overall mean was calculated.
Assessment of study quality
Study quality was assessed with the Newcastle-Ottawa Scale (NOS) for cohort studies and with a modified NOS for cross-sectional studies (Wells, 2000) , see Appendix 2, Tables 3 and 4 in Supplementary material. Classification of studies with low or high quality resulted from a median split of the total quality score.
Statistical analyses
Statistical analyses were performed in R (version 3.3.2. (Team RC., 2016) ) using the metafor package (version 2.0, (version 2.0., Viechtbauer (2010) ). Random-effects models were fitted using restricted maximum likelihood (REML) estimations. Pooled odds ratios (OR) with corresponding 95% confidence intervals (CI) were generated to examine the association between APOE genotype and affective symptoms. Both crude and fully adjusted model estimates were used. In case a study did not report effect sizes, contingency tables were extracted whenever possible to obtain the log OR and corresponding sampling variances. For a few studies this information was estimated L.C.P. Banning et al. Neuroscience and Biobehavioral Reviews 96 (2019) 302-315 Table 1 Characteristics of studies assessing APOE genotype in relation to affective symptoms in cognitively impaired subjects. Neuroscience and Biobehavioral Reviews 96 (2019) 302-315 = demographic information given per group, weighted overall mean was calculated; b = demographics given for total sample but APOE genotype only known for subset, assumption is made that there is no difference between demographical characteristics for those with and without APOE genotype available; c = age of onset; d = median (IQR); e = number and percentage of people with an education; f = number and percentage of people with less than 7 years education; g = instruction level; h = < 8 years (n = 48), 8-11 years (n = 60), > 11 years (n = 31); i = 36% of the subjects had not completed high school, 28% had completed high school, and 36% had completed at least some college; j = estimated score from Cognitive Abilities Screening Instrument (CASI); k = with prevalence of depression, sum of minor and major depression; l = "patients were asked if their sleep was satisfactory (yes or no) with confirmation by their caregivers. In case patients were unable to describe their sleep, preference was given to caregiver reports"; m = research criteria for depression.
L.C.P. Banning et al. Neuroscience and Biobehavioral Reviews 96 (2019) 302-315 based on figures (Levy et al., 1999; Park et al., 2015; van der Flier et al., 2006; Woods et al., 2009) . Funnel plot asymmetry, as an indicator for publication bias, was visually inspected by plotting effect sizes against their standard errors. In addition, Egger's regression test was conducted to test for significant asymmetry. The I 2 statistic was computed to quantify the proportion of variation across studies due to heterogeneity. Heterogeneity was considered to be small when I 2 ≤ 25%, moderate for I 2 = 26-74%, and large for I 2 ≥ 75% (Higgins et al., 2003) . First, analyses were performed per symptom by use of adjusted or unadjusted estimates. In case significant heterogeneity was present, the variation was examined further by conducting stratified analyses and meta-regression (e.g. setting, design, symptom assessment method, syndromal diagnosis, mean age, mean educational level, mean MMSE score, percentage of APOE ε4 carriers, percentage of patients with symptom present and study quality).
Results
Of 2,355 identified abstracts 92 were selected for full-text screening (see Fig. 1 ). Of these, 53 articles (57.6%) met inclusion criteria. Four additional studies were found from cross-references, but were excluded after full-text screening due to different reasons: matched subjects (Chung et al., 2016) , comment (Ballard et al., 1997) , animal study (Robertson et al., 2005) and unavailable record (Murphy et al., 1997) . ε4+, APOE ε4 allele carriers; ε4-, APOE ε4 allele non-carriers. * definition of APOE ε4 carriership differed per study: 21 studies included -next to the genotypes APOE ε3/ε4 and ε4/ε4 -also the genotype ε2/ε4 (Levy et al., 1999; Woods et al., 2009; Jefferson et al., 2001; Gabryelewicz et al., 2002; Liu et al., 2002; Lyketsos et al., 1997; Müller-Thomsen et al., 2002; Scarmeas et al., 2002; Spalletta et al., 2006; Xing et al., 2015; Farlow et al., 2004; Chang et al., 2004; De Oliveira et al., 2017; Engelborghs et al., 2006; Hirono et al., 1999; Craig et al., 2004; De Oliveira et al., 2014; D'Onofrio et al., 2011; Chen et al., 2012; Hollingworth et al., 2006; Mou et al., 2015) ; whereas 9 studies did not include ε2/ε4, e.g. because ε2/ε4 frequencies were too low or because of the protective effect of the ε2 allele (Forsell et al., 1997; Michels et al., 2012; Bowirrat et al., 2006; Harwood et al., 1999; Lopez et al., 1998; Monastero et al., 2006; Ramachandran et al., 1996; Borroni et al., 2006; Craig et al., 2006) ,and without specification in the remaining studies. Fig. 2 . Forest plot of the relationship between APOE ε4 carriership and presence of depression. Subanalyses on adjusted odds ratios and unadjusted odds ratios. APOE e4+ = APOE ε4 allele carriers; APOE e4-= APOE ε4 allele non-carriers; Dep + = depression present; Dep -= depression absent; CI = confidence interval.
Study characteristics
Characteristics of studies assessing APOE genotype in relation to affective symptoms (n = 53) are presented in Table 1 . The majority of subjects were from clinical research settings, such as (hospital based) memory clinics (42 studies with 11,536 subjects), of which 16 were multi-center studies. Subjects with MCI (n = 1,551) and AD dementia (n = 10,833) were the primary interest of the current study, although some studies did not differentiate AD from other types of dementia in their analyses (Woods et al., 2009; Forsell et al., 1997; Jefferson et al., 2001; Michels et al., 2012; Schmand et al., 1998; Steinberg et al., 2006) , adding 417 dementia subjects, resulting in a total of 12,801 (55.4% females) subjects.
Overall, DNA was prepared from blood and APOE genotypes were obtained by polymerase chain reaction (PCR) methods, except for two studies that used buccal cell swaps (Woods et al., 2009; Steinberg et al., 2006) . Thirty studies reported information on APOE ε4 carriership, 13 studies on zygosity (i.e. no ε4 allele, one or two alleles), 9 studies on allele frequencies (i.e. ε2, ε3, ε4) and 28 on distribution of genotypes (i.e. ε2/ε2, ε2/ε3, ε3/ε3, ε3/ε4, ε4/ε4).
Median splitting of the quality assessment score resulted in 56.5% of the cross-sectional studies (n = 46) scoring below the median (score of 4 out of 7) and in 44.4% of the longitudinal studies (n = 7) scoring below the median (score of 8 out 9).
Participant characteristics
As described above, data from in total 12,801 subjects were included for the present study. The pooled mean baseline characteristics were as follows: age 75.7 years (range 67.8 to 88.4), MMSE score 17.3 (range 10.4 to 26.9) and education 8.9 years (range 4.0 to 14.2). APOE ε4 carriership was known for 10,710 subjects (5,346 ε4-carriers, of whom 24.0% had additional information on zygosity). See Table 2 for number of subjects with affective symptoms present according to genotype.
Depression
Forty-one studies investigated the association between APOE genotype and depression. Based on the available data to calculate effect sizes, the results of 28 studies could be included in the meta-analysis (Levy et al., 1999; Park et al., 2015; van der Flier et al., 2006; Forsell et al., 1997; Michels et al., 2012; Schmand et al., 1998; Steinberg et al., 2006; Borroni et al., 2009; Bowirrat et al., 2006; Cantillon et al., 1997; Craig et al., 2005; Delano-Wood et al., 2008; Gabryelewicz et al., 2002; Harwood et al., 1999; Liu et al., 2002; Lopez et al., 1998; Lyketsos et al., 1997; Mackin et al., 2013; Monastero et al., 2006; Müller-Thomsen et al., 2002; Pink et al., 2015; Pritchard et al., 2007; Ramachandran et al., 1996; Scarmeas et al., 2002; Slifer et al., 2009; Spalletta et al., 2006; Xing et al., 2015; Zdanys et al., 2007) , representing 9,476 subjects (44.5% females). Overall, there was no association between APOE ε4 carriership and the presence of depression (OR = 1.09, 95% CI 0.98-1.22; Fig. 2 ). Similar results were found for adjusted estimates, hetero-and homozygotes. Based on unadjusted estimates, a positive association between APOE ε4 carriership and the presence of depression was found (OR = 1.23, 95% CI 1.08-1.40), with a small amount of heterogeneity (I 2 = 8.45%, p = 0.298), with an asymmetrical funnel plot (see Appendix 4, Fig. 4 in Supplementary material) and with suggestion of small-study effects (Egger test, p = 0.002). In meta-regression, higher mean MMSE score and less females included were shown to significantly increase the effect (resp. p = 0.025 and p = 0.046). Further, stratified analyses showed that the association only hold true for studies that were clinical based (but not population based), crosssectional studies (but not longitudinal) that assessed depressive Fig. 3 . Forest plot of the relationship between APOE ε4 carriership and presence of anxiety. Subanalyses on adjusted odds ratios and unadjusted odds ratios. APOE e4+ = APOE ε4 allele carriers; APOE e4-= APOE ε4 allele non-carriers; Anx + = anxiety present; Anx -= anxiety absent; CI = confidence interval.
symptoms with self-and clinician reports (but not caregiver report). The overall effects and heterogeneity across studies, also within stratifications, are shown in Appendix 3, Table 1 in Supplementary material. Thirteen studies could not be included due to incomplete data reporting, and in line with the results of the meta-analysis, nearly all studies did not find an association between APOE ε4 and depression: not with severity of depression (Class et al., 1997; Farlow et al., 2004) , nor with presence of depression (Jefferson et al., 2001; Class et al., 1997; Borroni et al., 2006; Chang et al., 2004; De Oliveira et al., 2017; Engelborghs et al., 2006; Flirski et al., 2012; Hirono et al., 1999; Holmes et al., 1996 Holmes et al., , 1998 Yoo et al., 2014) . Only one study reported an association between APOE ε4 and presence of depression in subjects with AD (Fritze et al., 2011) , which is a multi-center, clinically based, cross-sectional study that assessed depressive symptoms using caregiver-reports.
Anxiety
Seventeen studies investigated the association between APOE genotype and anxiety. Results of 11 studies were included in the metaanalysis (Levy et al., 1999; Park et al., 2015; van der Flier et al., 2006; Michels et al., 2012; Steinberg et al., 2006; Gabryelewicz et al., 2002; Monastero et al., 2006; Pritchard et al., 2007; Spalletta et al., 2006; Xing et al., 2015; Zdanys et al., 2007) , representing 4,148 subjects (44.8% females). Overall, there was no association between APOE ε4 carriership and the presence of anxiety (OR = 1.25, 95% CI 0.97-1.62; Fig. 3 ). Similar results were found for adjusted estimates, hetero-and homozygotes. Based on unadjusted estimates, a positive association was found (OR = 1.53, 95% CI 1.09-2.15), with moderate heterogeneity (I 2 = 66.89%, p = 0.017), with an asymmetrical funnel plot (see Appendix 4, Fig. 6 in Supplementary material) and with suggestion of small-study effects (Egger test, p = 0.014). In meta-regression, assessment method was identified as having a significant effect on the association (p < 0.001) and was therefore used to further stratify the metaanalysis thereby reducing I 2 substantially (see Fig. 4 ). Additionally, subgroup analysis showed that the overall effect was due to one longitudinal study (Pritchard et al., 2007) , as pooling of the remaining 6 cross-sectional studies resulted in no association found (OR = 1.47, 95% CI 0.99-2.19). The overall effects and heterogeneity across studies, also within stratifications, are shown in Appendix 3, Table 2 in Supplementary material. Six studies could not be included and, in line with the results of the meta-analysis, nearly all studies did not found an association between APOE ε4 and anxiety (Farlow et al., 2004; Borroni et al., 2006; De Oliveira et al., 2017; Flirski et al., 2012; Hirono et al., 1999) . Only one study reported APOE ε4 carriers having more severe symptoms of anxiety in subjects with AD (Yoo et al., 2014) , which is a single-center, clinically based, cross-sectional study that assessed anxiety symptoms using caregiver-reports.
Apathy
Sixteen studies investigated the association between APOE genotype and apathy. Results of 9 studies were included in the meta-analysis (Levy et al., 1999; Park et al., 2015; van der Flier et al., 2006; Steinberg et al., 2006; Monastero et al., 2006; Pink et al., 2015; Spalletta et al., 2006; Xing et al., 2015; Zdanys et al., 2007) , representing 3,194 subjects (49.5% females). There was no association between APOE ε4 carriership and the presence of apathy (OR = 1.00, 95% CI 0.84-1.19; Fig. 5 ). Similar results were found for adjusted and unadjusted estimates, for hetero-and homozygotes. The overall effects and (possible Fig. 4 . Forest plot of the relationship between APOE ε4 carriership and presence of anxiety, unadjusted estimates. Subanalyses on caregiver (all AD patients) vs. clinician report (MCI and dementia patients). APOE e4+ = APOE ε4 allele carriers; APOE e4-= APOE ε4 allele non-carriers; Anx + = anxiety present; Anx -= anxiety absent; CI = confidence interval. sources of -) heterogeneity across studies, within stratifications, are shown in Appendix 3, Table 3 in Supplementary material.
Seven studies could not be included and, in line with the results of the meta-analysis, the majority did not found an association between APOE ε4 and apathy (Farlow et al., 2004; Borroni et al., 2006; Flirski et al., 2012; Hirono et al., 1999; Vercelletto et al., 2002) . Two studies report an association, one with APOE ε4 carriers having more severe symptoms of apathy (Yoo et al., 2014) whereas the other reports APOE ε4 carriers having less symptoms of apathy (De Oliveira et al., 2017) , although this effect was only found in moderately severe AD dementia.
Agitation
Twenty studies investigated the association between APOE genotype and agitation. Results of 12 studies were included in the metaanalysis (Levy et al., 1999; Park et al., 2015; van der Flier et al., 2006; Steinberg et al., 2006; Monastero et al., 2006; Pink et al., 2015; Pritchard et al., 2007; Spalletta et al., 2006; Xing et al., 2015; Zdanys et al., 2007; Christie et al., 2012; Craig et al., 2004) , representing 4,772 subjects (54.3% females). Overall, there was no association between APOE ε4 carriership and the presence of agitation (OR = 1.07, 95% CI 0.94-1.20; Fig. 6 ). Similar results were found for adjusted and unadjusted estimates, for hetero-and homozygotes. The overall effects and (possible sources of -) heterogeneity across studies, within stratifications, are shown in Appendix 3, Table 4 in Supplementary material.
Eight studies could not be included and, in line with the results of the meta-analysis, the majority did not found an association between APOE ε4 and agitation (Farlow et al., 2004; Borroni et al., 2006; De Oliveira et al., 2017; Flirski et al., 2012; Hirono et al., 1999; Yoo et al., 2014; Schutte et al., 2011) . One study reports a positive association between APOE ε4 and agitation in subjects with dementia (Woods et al., 2009) , which is a single-center, clinically based, cross-sectional study that assessed symptoms of agitation with clinician ratings.
Irritability
Fourteen studies investigated the association between APOE genotype and irritability. Results of 8 studies were included in the metaanalysis (Levy et al., 1999; Park et al., 2015; van der Flier et al., 2006; Steinberg et al., 2006; Monastero et al., 2006; Spalletta et al., 2006; Xing et al., 2015; Zdanys et al., 2007) , representing 2862 subjects (50.0% females). Overall, there was no association between APOE ε4 carriership and the presence of irritability (OR = 1.17, 95% CI 0.93-1.48; Fig. 7) . Similar results were found for adjusted and unadjusted estimates, for hetero-and homozygotes. The overall effects and (possible sources of -) heterogeneity across studies, within stratifications, are shown in Appendix 3, Table 5 in Supplementary material.
Six studies could not be included and, in line with the results of the meta-analysis, none of the studies found an association between APOE ε4 and irritability (Farlow et al., 2004; Borroni et al., 2006; De Oliveira et al., 2017; Flirski et al., 2012; Hirono et al., 1999; Yoo et al., 2014) .
Sleep disturbances (night-time behaviour and sleep disturbances)
Ten studies investigated the association between APOE genotype and sleep disturbances. Results of 8 studies were included in the metaanalysis Monastero et al., 2006; Pink et al., 2015; Xing et al., 2015; Zdanys et al., 2007; Flirski et al., 2012; Craig et al., 2006; De Oliveira et al., 2014) , representing 2,749 subjects (53.4% females). Overall, there was no association between APOE ε4 carriership and the presence of sleep disturbances (OR = 0.89, 95% CI 0.68-1.18; Fig. 8 ). Similar results were found for adjusted and unadjusted estimates, for hetero-and homozygotes. The overall effects and (possible sources of -) heterogeneity across studies, within Fig. 5 . Forest plot of the relationship between APOE ε4 carriership and presence of apathy. Subanalyses on adjusted odds ratios and unadjusted odds ratios. APOE e4+ = APOE ε4 allele carriers; APOE e4-= APOE ε4 allele non-carriers; Apa + = apathy present; Apa -= apathy absent; CI = confidence interval.
stratifications, are shown in Appendix 3, Table 6 in Supplementary material.
Two studies could not be included, of which one reported APOE ε4 carriers experiencing less sleep disturbances (Borroni et al., 2006) , whereas the other study found no association (Yoo et al., 2014) in subjects with AD.
Subsyndromes
Six studies assessed APOE genotype in relation to subsyndromes of neuropsychiatric symptoms (NPS). Of these, two used the European Alzheimer Disease Consortium factor analysis (Aalten et al., 2007 (Aalten et al., , 2008 that formed a psychotic, affective, hyperactive and apathetic subsyndrome. APOE ε4 carriers were found to have an increased risk of affective and apathetic syndromes (D'Onofrio et al., 2011) whereas another study did not find associations (Hall et al., 2014) . One study identified agitation/aggression-delusion, euphoria-disinhibition, depression-apathy, hallucination-nighttime behaviour, and appetite as subsyndromes and found APOE ε4 carriers to have higher scores in the agitation/aggression-delusion subsyndrome (Chen et al., 2012 ). Another study identified behavioural dyscontrol (euphoria, disinhibition, aberrant motor behaviour, and sleep and appetite disturbances), psychosis (delusions and hallucinations), mood (depression, anxiety, and apathy), and agitation (aggression and irritability) subsyndromes, of which none was associated with APOE ε4 (Hollingworth et al., 2006) . Another identified disorders of thought, disorders of perception, disorders of mood, disorders of behaviour (into wandering and stereotypical behaviours) and neurovegetative features; none of these subsyndromes were associated with APOE ε4 (Holmes et al., 1996) . One study grouped anxiety, depression and psychotic symptoms together and report APOE ε4 carriers having more often these symptoms (Mou et al., 2015) .
Discussion
In this systematic review and meta-analysis an overview is provided of association data between APOE genotype and affective symptoms, pooling data from 12,801 subjects with cognitive decline. Overall, it could be concluded that meta-analyses showed no association between APOE genotype and depression, anxiety, apathy, agitation, irritability and sleep disturbances, neither for APOE ε4 carriership nor zygosity. These results were in line with descriptive results of studies that could not be included in meta-analysis due to incomplete data-reporting.
This meta-analysis and systematic review extends on previous reviews on the topic (Flirski et al., 2011; Panza et al., 2012) . While these reviews suggested that assessing APOE status in either ε4-carriership or number of ε4-alleles possibly could account for the discrepancy in findings, analyses of the current study on APOE ε4 carriership and zygosity all pointed in the same direction: namely, there is no association between APOE genotype and affective symptoms. It was also suggested that differences in sample composition could be a possible source of discrepancy (Flirski et al., 2011; Panza et al., 2012) . Indeed, moderate heterogeneity that was observed for the positive association for (unadjusted estimates) anxiety was (partly) explained by variation in diagnostic groups included. However, the only study including MCI subjects next to subjects with dementia was also the only one using clinician reported presence of anxiety symptoms instead of caregiver reported symptoms (Michels et al., 2012) . Thus, it is difficult to disentangle the contributing effect of underlying heterogeneity. Further, removal of studies that did not differentiate between types of dementia from meta-analyses (i.e. number of subjects with AD dementia was not specified (Forsell et al., 1997; Michels et al., 2012; Schmand et al., 1998; Steinberg et al., 2006) ) did not change the results. Of the five studies including MCI subjects, only one specified MCI subtypes (i.e., amnestic/non-amnestic, single/multiple-domain) (Pink et al., 2015) . This subtyping however, was used for another research question addressed by the paper (i.e. to examine whether an interaction between subtype and any NPS influenced the outcome of incident dementia). MCI was diagnosed according to (or in accordance with) Petersen criteria (Michels et al., 2012; Mackin et al., 2013; Pink et al., 2015; Farlow et al., 2004; Flirski et al., 2012) . It is important to note that all diagnostic criteria employed were syndromal (i.e., based on clinical consequences of the disease, such as the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA, McKhann et al. (1984) ), DSM, ICD-10 and National Institute on Aging-Alzheimer's Association (NIA-AA, McKhann et al. (2011)) criteria and not, as was recently suggested by the NIA-AA AT(N) research framework (Jack et al., 2017) , biologically based. It is therefore currently not possible to explore the differential effect between MCI subtypes or disease etiologies. Increased incorporation in future research of the NIA-AA criteria (Jack et al., 2017) will provide an interesting opportunity for this.
The use of a wide-range of instruments to assess affective symptoms can be a possible cause of heterogeneity. Meta-regression findings showed that this was indeed the case for anxiety (as described above) and depression, but not for the other symptoms. Additionally, measuring symptoms vs. a syndromal diagnosis was not identified as having a significant effect on the association. Further, as overall burden of NPS is observed to be more severe in later stages of the disease, the previous mentioned reviews concluded that disease severity or disease duration should be corrected for (Flirski et al., 2011; Panza et al., 2012) , something that few studies did. Indeed, disease severity based on MMSE score showed to explain some of the variance across depression, agitation and irritability studies (see Appendix 4, Tables 1, 4 and 5 in Supplementary material).
In addition to the above-described factors (i.e. diagnostic groups included, symptom assessment (self-or proxy) and definitions (symptom or disorder) used), study design and setting were also identified to explain the observed heterogeneity for depression and anxiety studies. That is, the association only held true for depression in crosssectional and clinical studies (but not longitudinal or population based studies) and for anxiety the positive effect was driven by one longitudinal study (Pritchard et al., 2007) . Further, age and MMSE score were identified in meta-regression analysis as explaining some of the variance across studies. Thus, it is very likely that, in case these studies would have corrected for sample characteristics, the association would have disappeared.
The tendency of affective symptoms to wax and wane over time, e.g. depression decreases whereas apathy increases over time (Aalten et al., 2005) , and the inherent limitation of cross-sectional studies to interpret causality in the association implies that the association should be assessed in longitudinal designs. Indeed, only a limited number of studies assessing the prospective associations could be identified in the literature search (n = 7). The majority of these studies did not report the predictive value of APOE genotype on the development of affective symptoms over time, although one study suggested a protective effect of the ε4-allele in MCI subjects for developing sleep disturbances (Flirski et al., 2012) . Three studies stratified their sample according to gender, and showed associations of APOE ε4 and affective symptoms to be higher within female subjects as compared to males (depression and irritability, resp. (Delano-Wood et al., 2008; Xing et al., 2015) ), although another study reported the opposite, with a (negative) association being stronger in males (Bowirrat et al., 2006) . Here, the effect between APOE ε4 carriership and depression and between APOE ε4 homozygosity and apathy was found to be smaller when more females were included, i.e. contrasting prior results.
In this meta-analysis, three studies, all related to depression, had a sample size smaller than 100 subjects (resp. n = 46, 87 and 43; (Schmand et al., 1998; Ramachandran et al., 1996 ; Scarmeas et al., Fig. 7 . Forest plot of the relationship between APOE ε4 carriership and presence of irritability. Subanalyses on adjusted odds ratios and unadjusted odds ratios. APOE e4+ = APOE ε4 allele carriers; APOE e4-= APOE ε4 allele non-carriers; Irri + = irritability present; Irri -= irritability absent; CI = confidence interval.
2002)) but exclusion of these studies did not change the results (OR = 1.09, 95% CI 0.98-1.22). Although methodological quality of studies was found to be moderate, it did not influence the effects found. The quality ratings might be underestimated, as ratings were based on information provided in the paper and not all included studies had the APOE genotype -affective symptom association as main research question (Jefferson et al., 2001; Schmand et al., 1998; Harwood et al., 1999; Mackin et al., 2013; Pink et al., 2015; Schutte et al., 2011; Hall et al., 2014) .
The findings of this meta-analysis have implications for the view on the relationship between affective symptoms and AD, of which the exact mechanisms are still not fully understood. Possibly, the affective symptomatology is a non-cognitive manifestation of already ongoing AD pathology or act as a risk factor for AD, where affective symptoms induce a biological cascade in the brain. Even though affective symptoms were not found to be associated with APOE genotype, this does not undermine the clinical importance of identifying and monitoring the highly prevalent affective symptoms in (prodromal) AD dementia. The complex nature of affective symptoms indicates that clinicians should approach affective symptoms in a multifactorial manner.
Strengths and limitations
By using all the available evidence, pooling a large amount of information and adjusting for a large number of known confounders, this study concluded that APOE genotype is not associated with affective symptomatology in MCI and AD dementia. The current study showed that factors that fueled discussions as potential sources of discrepancies do not contribute to the contrasting findings. As the percentage of APOE ε4 carriers was found to be higher in clinical settings than in population settings (resp. 50.9 and 40.8%), studies per study setting (i.e. population vs. clinical studies) were stratified in order to minimize the risk that the results were primarily driven by referral bias of the clinical samples.
Some methodological issues warrant further discussion. Analyses were not limited to studies reporting fully adjusted ORs only, as this would have led to the exclusion of 63% of the estimates. Thus, it is possible that confounders influenced the associations. Further, adjusted estimates were corrected for different sets of possible confounders. However, most studies adjusted minimally for age and sex -where additional adjusting for education or disease severity did not change the results. In addition, although a large number of confounders were included in the meta-regressions, some factors were not commonly reported at study level (e.g. educational level) and thus could not be considered for all symptoms in the analyses. Surprisingly, only six studies provided information on psychiatric history of their subjects. Except for one study (Lyketsos et al., 1997) , these data were used for descriptive purposes only (Forsell et al., 1997; Cantillon et al., 1997; Craig et al., 2005; Holmes et al., 1998; Craig et al., 2004) . Studying underlying biological mechanisms of NPS in dementia and not controlling for psychiatric history could have implications for the interpretation of the findings. That is, first-time onset of depressive symptoms in AD is probably due to a different disease etiology when compared to depressive symptoms in AD that are recurrent (i.e. history of depressive disorder). In addition, presence of somatic comorbidities or prescription of medication potentially confounds the relationship between APOE genotype and affective symptoms. However, only one (De Oliveira et al., 2017) 2014; D'Onofrio et al., 2011) studies that have provided information on medication use (e.g. antidepressants or antipsychotics) corrected for this in their analyses; none of the seven studies (Woods et al., 2009; Forsell et al., 1997; Steinberg et al., 2006; Borroni et al., 2009; Bowirrat et al., 2006; Lopez et al., 1998; Borroni et al., 2006) mentioning somatic comorbidities (e.g. hypertension, diabetes and cardiovascular diseases) corrected for this in their analyses.
Finally, the most important limitation is, although inherent to genetic studies, the fact that investigating the association between one gene and complex traits such as affective symptoms is an oversimplification. The effect of individual polymorphisms, here APOE ε4, is usually weak and requires large cohorts to demonstrate associations. It is more probable that gene-environment interactions take place or that multiple genes are involved, which is an important topic for future research. In addition, future work should focus on the interplay between other biological factors, such as alterations in the hypothalamuspituitary-adrenal axis (Sierksma et al., 2010) , (nor)adrenergic, serotoninergic and dopaminergic neurotransmitter systems (Vermeiren et al., 2013) , neuroinflammation markers (Holmgren et al., 2014) amyloid plaques and neuronal injury markers (Ramakers et al., 2013) , and cerebrovascular changes that have been linked to affective symptoms in AD. An important starting point can be the interpretation of neuropathological evidence, such as amyloid plaques and neuronal injury markers.
